Raya Therapeutic Announces Selection of one of its 5 compounds onto the EXPERTS-ALS Clinical Platform Trial
Company Logo Positive data from this clinical study could lead to a registration trial of the compound for the treatment of ALS/MND. MONTREAL, QUEBEC, CANADA, September 2, 2025 /EINPresswire.com/ — Raya Therapeutic Inc., (“Raya”) a mission-driven company focused on the treatment of ALS and other neurodegenerative diseases, announces that one of its five clinical stage ...
Read More